Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Other Working Capital Changes (2016 - 2025)

Lineage Cell Therapeutics' Other Working Capital Changes history spans 16 years, with the latest figure at $1.0 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 156.47% year-over-year to $1.0 million; the TTM value through Dec 2025 reached -$46000.0, up 90.59%, while the annual FY2025 figure was -$46000.0, 90.59% up from the prior year.
  • Other Working Capital Changes reached $1.0 million in Q4 2025 per LCTX's latest filing, down from $2.7 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $8.5 million in Q3 2022 to a low of -$4.9 million in Q1 2022.
  • Average Other Working Capital Changes over 5 years is -$427700.0, with a median of -$533500.0 recorded in 2024.
  • Peak YoY movement for Other Working Capital Changes: tumbled 8061.54% in 2022, then surged 829.6% in 2025.
  • A 5-year view of Other Working Capital Changes shows it stood at -$1.2 million in 2021, then soared by 106.14% to $71000.0 in 2022, then crashed by 2366.2% to -$1.6 million in 2023, then soared by 124.98% to $402000.0 in 2024, then soared by 156.47% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Other Working Capital Changes are $1.0 million (Q4 2025), $2.7 million (Q3 2025), and -$3.1 million (Q2 2025).